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Antibodies from multiple sclerosis 
patients preferentially recognize 
hyperglucosylated adhesin of non-
typeable Haemophilus influenzae
Marthe T. C. Walvoort1,*, Chiara Testa2,3,*, Raya Eilam4, Rina Aharoni5, Francesca Nuti2,6, 
Giada Rossi2,3, Feliciana Real-Fernandez2,3, Roberta Lanzillo7, Vincenzo Brescia Morra7, 
Francesco Lolli8, Paolo Rovero2,3, Barbara Imperiali1 & Anna Maria Papini2,6,9
In autoimmune diseases, there have been proposals that exogenous “molecular triggers”, i.e., specific 
this should be ‘non-self antigens’ accompanying infectious agents, might disrupt control of the adaptive 
immune system resulting in serious pathologies. The etiology of the multiple sclerosis (MS) remains 
unclear. However, epidemiologic data suggest that exposure to infectious agents may be associated 
with increased MS risk and progression may be linked to exogenous, bacterially-derived, antigenic 
molecules, mimicking mammalian cell surface glycoconjugates triggering autoimmune responses. 
Previously, antibodies specific to a gluco-asparagine (N-Glc) glycopeptide, CSF114(N-Glc), were 
identified in sera of an MS patient subpopulation. Since the human glycoproteome repertoire lacks 
this uniquely modified amino acid, we turned our attention to bacteria, i.e., Haemophilus influenzae, 
expressing cell-surface adhesins including N-Glc, to establish a connection between H. influenzae 
infection and MS. We exploited the biosynthetic machinery from the opportunistic pathogen  
H. influenzae (and the homologous enzymes from A. pleuropneumoniae) to produce a unique set of 
defined glucosylated adhesin proteins. Interestingly we revealed that a hyperglucosylated protein 
domain, based on the cell-surface adhesin HMW1A, is preferentially recognized by antibodies from sera 
of an MS patient subpopulation. In conclusion the hyperglucosylated adhesin is the first example of an 
N-glucosylated native antigen that can be considered a relevant candidate for triggering pathogenic 
antibodies in MS.
Multiple sclerosis (MS) is the most common debilitating neurological disease of young adults in the developed 
world. It is a complex heterogeneous, inflammatory disorder characterized by a loss of the myelin sheath sur-
rounding the nerve axons in the central nervous system (CNS). MS is considered an autoimmune disease in 
which the possible role of infections as triggering events is actively debated. In fact, it is unclear how adaptive 
immune responses are involved in CNS damage, and whether such responses are the pathogenic root cause or 
just an epiphenomenon in MS. The defined cause of MS is still unknown, but it is established that complex 
1Departments of Biology and Chemistry Massachusetts Institute of Technology 77 Massachusetts Ave., Cambridge, 
MA, USA. 2French-Italian Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, University 
of Florence, 50019, Sesto Fiorentino, Italy. 3Department of Neurosciences, Psychology, Drug Research and Child 
Health - Section of Pharmaceutical Sciences and Nutraceutics, University of Florence, Via Ugo Schiff 6, 50019, Sesto 
Fiorentino, Italy. 4Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, 761001, Israel. 
5Department of Immunology, The Weizmann Institute of Science, Rehovot, 761001, Israel. 6Department of Chemistry 
“Ugo Schiff”, University of Florence, Via della Lastruccia 13, 50019 Sesto Fiorentino, Italy. 7Multiple Sclerosis 
Clinical Care and Research Centre, Department of Neurosciences, Reproductive Sciences and Odontostomatology, 
Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy. 8Department of Biomedical, Experimental and 
Clinical Sciences, University of Florence, Viale Morgagni 50, 50134 Firenze, Italy. 9PeptLab@UCP and Laboratory of 
Chemical Biology EA4505, Université Paris-Seine, 5 Mail Gay-Lussac, 95031 Cergy-Pontoise, France. *These authors 
contributed equally to this work. Correspondence and requests for materials should be addressed to B.I. (email: 
imper@mit.edu) or A.M.P. (email: annamaria.papini@unifi.it)
Received: 26 April 2016
Accepted: 21 November 2016
Published: 23 December 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:39430 | DOI: 10.1038/srep39430
interactions between environmental factors and multiple gene products are involved1–3. Epidemiologic data have 
identified several infectious factors that may be associated with increased MS risk4. Emerging hypotheses con-
sider that the progression of MS is linked to exogenous infectious agents expressing antigenic molecules, which 
mimic the structure and/or conformation of endogenous mammalian surface glycoproteins and/or glycolipids5,6. 
This molecular mimicry between self-molecules and exogenous antigens could lead to activation of autoreactive 
lymphocytes thereby establishing clinical symptoms. Although an antibody-mediated demyelination mechanism 
might contribute to the immunopathology of MS, this hypothesis has never been unequivocally demonstrated. In 
fact, the role of antibody recognition in MS is controversial and the cause of significant debate, possibly because 
antigens employed in immunoassays do not faithfully recapitulate the putative native entities implicated in trig-
gering the immunologic response7–9.
Myelin Oligodendrocyte Glycoprotein (MOG), a glycoprotein in the CNS, has emerged as a potential autoan-
tigen involved in demyelination processes fundamental to MS. While the importance of anti-MOG autoanti-
bodies has been established in pediatric demyelination10, their role in adult MS patients is still speculative11,12. 
Intrigued by the possible role of MOG glycosylation in pathogenic autoantibody generation, a series of peptides 
and glycopeptides were investigated for their binding to autoantibodies present in MS patient sera13,14. This led to 
the identification of an antigenic probe termed CSF114(N-Glc) (Fig. 1a), which was used to detect, isolate, and 
characterize antibodies as potential biomarkers in a subpopulation of MS patients15,16. This was the first report 
that an aberrant asparagine-glucosylation (N-Glc) was implicated in triggering formation of autoantibodies in 
MS. The high specificity and affinity with which the CSF114(N-Glc) is recognized and binds to antibodies in MS 
patient sera were ascribed to two critical structural aspects of the biomarker: the N-linked β -d-glucopyranosyl 
moiety17 and a β -hairpin structure, which optimally exposes the minimal Asn(N-Glc) epitope, both essential 
for autoantibody recognition14. At the time that the CSF114(N-Glc) antigen was identified, there was a paucity 
of evidence for the presence of Asn(N-Glc) in eukaryotic proteins. Apart from a single report identifying an 
N-glucose moiety in the mammalian glycoprotein laminin18, this specific post-translational modification was 
virtually absent in eukaryotes, and observed only rarely in selected archaea19. We therefore concluded that it was 
unlikely that the antibodies that reacted with CSF114(N-Glc) had been elicited specifically to a human protein 
or a simple mutation to a human protein as is the case with neuromyelitis optica (NMO), which is an autoim-
mune disease with demyelination of the spinal cord and optic nerve with clinical similarity to MS but specifically 
marked by anti-human aquaporin-4 antibodies20,21. However, recent biochemical, analytical and bioinformatics 
approaches have uncovered an expansive repertoire of prokaryote-specific glycoprotein conjugates that by vir-
tue of their cell-surface localization may represent putative important antigens involved in the development of 
Figure 1. Schematic representation of the enzymatic reaction and putative N-glucosylation sites on 
HMW1ct. (a) Structure of CSF114(N-Glc). (b) Glucosylation of Asn in the consensus senquence NX(S/T), 
catalyzed by HMW1C, (PDB: 3Q3H). (c) Schematic representation of HMW1A, displaying the extended signal 
peptide (SP), pre-protein (PP), mature HMW1A, and the HMW1ct fragment (magnification is an I-TASSER29,30 
model of HMW1ct, with glycosylation sites 1, 2, 5, 6 in magenta, and remaining sites in blue).
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autoimmune diseases22. Interestingly, in 2003 St Geme et al. first reported that protein asparagine-glucosylation 
is a modification found on HMW1 adhesin in non-typeable Haemophilus influenzae23,24. Subsequently, in 2008 
it was established that the bacterial N-glucosylation is performed by the cytoplasmic HMW1C glycosyltrans-
ferase using UDP-glucose as the glycosyl donor (Fig. 1b). Interestingly, the structure of the homologous HMW1C 
from Actinobacillus pleuropneumoniae was reported in 201125 and later, a detailed biochemical evaluation of the 
Ap HM1WC revealed a relaxed substrate specificity. Nevertheless, UDP-Glc is unequivocally the preferred sub-
strate over UDP-Gal (UDP-Glc: kcat/KM = 502.8 M−1 s−1, UDP-Gal: kcat/KM = 1.3 M−1 s−1)26. The HMW1Cs from 
A. pleuropneumoniae and H. influenzae are some of the first examples of soluble bacterial protein glycosyltrans-
ferases that are capable of performing N-glycosylation with simple hexoses (i.e., glucose) on asparagine residues 
in conserved Asn-Xaa-Ser/Thr motifs27. We hypothesized that a bacterial infection, accompanied by cell-surface 
presentation of N-glucosylated adhesins, could stimulate autoreactive MS immune cells to trigger an antibody 
response through a molecular mimicry mechanism. Using the glycosylation machinery from H. influenzae (and 
homologues of A. pleuropneumoniae), we produced and purified glycoproteins with defined N-glucosylation 
patterns. These antigens were preferentially recognized by antibodies from MS patients. Moreover, the purified 
antibodies were shown to cross-react with the myelin in the spinal cord tissue in an experimental animal model 
of MS.
Results
Biochemical production of purified glucosylated adhesin fragments. In order to identify the 
cross-reactivity between N-glucosylated adhesin fragments from H. influenzae and autoantibodies from MS 
patient sera, we established methods to generate a well-defined set of N-glucosylated protein antigens using 
biochemical techniques. We selected the C-terminal fragment of the HMW1A adhesin (residues 1205–1536, 
termed HMW1ct), which has been reported to be well expressed, soluble, and stably folded28. This domain of the 
HMW1A adhesin (see Supplementary Fig. 1 for the sequence) contains 12 putative N-glucosylation sites, of which 
some appear exposed on turns as predicted in the I-TASSER computational model of the protein (Fig. 1c)29,30. 
Mass spectrometry24 has revealed that sites 5, 6, and 7 (Fig. 1c) are found to be glycosylated in H. influenzae, 
but other reports suggest different glycosylation patterns both in vitro and in vivo31,32.
Similarly, the N-glucosyltransferase (HMW1C) homolog from A. pleuropneumoniae was employed for 
N-glucosylation because of its high expression and stability and the ability to produce glucosylated HMW1ct 
fragments28. The glucosylated HMW1ct antigen, I(Glc), was prepared by simultaneous co-expression of adhesin 
HMW1ct and N-glucosyltransferase HMW1C in E. coli33, that has an intracellular UDP-Glc concentration 
of 1–2 mM34. Using this method, I(Glc) was obtained as a mixture of three N-glucosylated HMW1ct variants 
containing 7, 8, and 9 glucose moieties on Asn in NX(S/T) sequons in a 1:1:1 ratio (Supplementary Table 1). 
Tryptic digest and MS/MS analysis was performed to determine which of the potential N-glycosylation sites 
were modified (Supplementary Table 2). Inspired by the model generated using the I-TASSER program, gly-
cosylation sites in HMW1ct were sequentially removed using site-directed mutagenesis, giving antigens that 
display 5/6 N-Glc moieties, II(Glc), 4 spatially proximal N-Glc moieties (antigen III(Glc)), a set of four unrelated 
N-Glc positions (antigen IV(Glc)), and an antigen containing just two proximal N-Glc moieties (antigen V(Glc)) 
(Supplementary Table 1). These antigens were also produced in the corresponding non-glucosylated forms (I-V).
Antibodies in MS patient sera recognize N-glucosylated adhesin HMW1ct-Glc antigens. We 
investigated the ability of I(Glc) and the non-glucosylated protein I to detect IgM and IgG antibodies in sera of 
MS patients (Fig. 2a,b) and normal blood donors (NBDs) (Fig. 2c,d) using Solid-Phase ELISA (SP-ELISA).
The new hyperglucosylated protein I(Glc) detected IgM and IgG in MS patient sera and discriminated 
between the recruited population of 126 MS patients and 112 NBDs (IgM: p < 0.0003, IgG: p < 0.0141; 
Supplementary Fig. 2). Interestingly, the synthetic mono-glucosylated antigenic probe CSF114(N-Glc) was pre-
viously reported to discriminate between patients and NBDs with a similar trend, but much lower significance in 
the case of IgG (Supplementary Fig. 3)14,15, suggesting that hyperglucosylation of the bacterial adhesin protein, 
leading to the antigen I(Glc), favorably affects antibody recognition in MS. At variance, the non-glucosylated 
protein I did not discriminate between MS and NBD sera, and NBD sera presented a similar level of antibodies 
interacting with both the glucosylated I(Glc) and non-glucosylated I antigens. The relatively high titers observed 
for both antigens I and I(Glc) with NBD sera is not surprising as H. influenzae is a rather ubiquitous human path-
ogen to which most adults have been exposed. This results in the development of antibodies against epitopes that 
do not include the Glc moiety, but are shared by both I and I(Glc) (Supplementary Fig. 2). Significantly, the MS 
patient sera revealed to be highly populated with antibodies against the hyperglucosylated protein I(Glc), which 
suggests the recognition of an epitope specifically displayed on I(Glc).
Antibody detection in MS sera is N-Glc dependent. The relatively high antibody titers obtained 
from the NBD sera (Fig. 2c,d) suggest that common protein epitopes shared by antigens I(Glc) and I may inter-
fere with the detection of significant and distinct epitopes introduced by protein N-glucosylation. To quantify 
the antibody binding to I(Glc) and non-glucosylated analog I in both MS patient and NBD sera, an inhibition 
experiment was performed. A significant difference in antibody binding between glucosylated antigen I(Glc) 
(pIC50 = 7.67 ± 0.28–8.65 ± 0.10) and non-glucosylated antigen I (pIC50 = < 5.0) was observed for MS patient 
sera (Table 1). As anticipated, based on the total antibody titer experiments (Fig. 2), little difference in antibody 
binding was observed between antigens I(Glc) (pIC50 = 6.37 ± 0.52–7.20 ± 0.29) and I (pIC50 = 5.92 ± 0.52–
7.84 ± 0.42) in NBD sera (Table 1). This observation holds true independently from CSF114(N-Glc) positivity. 
In fact, two of the NBD samples are CSF114(N-Glc) positive (NBD2 and NBD4), while two are negative (NBD1 
and NBD3).
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Next, we explored the hypothesis that the N-Glc modification is a key determinant only for MS serum anti-
bodies and that antibodies in NBD sera recognize protein epitopes shared by both the modified and unmodified 
proteins. Using the purified antigens I(Glc) and I, an immunoaffinity-based fractionation was performed for 
representative MS (MS 1) and NBD (NBD 1) sera, as outlined schematically in Fig. 3a.
The NBD1 and the MS1 sera were applied separately to a Sepharose column bearing immobilized 
non-glucosylated adhesin I and the flow-through (FT1) and elution (Elu2) were collected. In the case of MS1, the 
un-retained FT1 fraction was loaded on a second column, bearing the immobilized glucosylated protein antigen 
I(Glc). Retained IgGs were eluted from both columns separately (Elu2 and Elu4), and their activities were deter-
mined by SP-ELISA (Fig. 3b).
The FT1 from NBD1 displayed a remarkable decrease in IgG antibody recognition both to I(Glc) and the 
non-glucosylated I, suggesting that all antibody reactivity had been retained on the I-immobilized column, and 
that these antibodies have a similar titer for both antigens (Fig. 3b). This confirms that antibodies in NBD sera 
recognize structural protein epitopes rather than those associated with N-glucosylation (Supplementary Fig. 4). 
Figure 2. Data distribution of measured SP-ELISA absorbances. (a) Total IgM and (b) IgG titers in 126 MS 
patient sera detected by SP-ELISA, comparison between the antigen I(Glc), and the non-glucosylated analog 
I. (c) Total IgM and (d) IgG titers in 112 NBD sera detected by SP-ELISA, comparison between I(Glc) antigen 
and the non-glucosylated analog I. MS patient and NBD sera selected for the detailed analysis are marked as red 
dots and circles.
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In contrast, with the MS1 serum, FT1 only displayed a significant decrease in anti-I antibodies, which 
had been retained on the first column (Fig. 3b). Indeed, when the resulting elution (Elu2) was purified with 
I(Glc)-immobilized Sepharose (second column), a high antibody reactivity with I(Glc) resulted (Elu4, Fig. 3b), 
which was not concentration dependent (Supplementary Fig. 5). These results together strongly support that MS 
patient sera in contrast to the NBD sera have a relatively high level of antibodies against the hyperglucosylated 
antigen I(Glc).
MS antibodies detect an epitope shared by CSF114(N-Glc) and HMW1ct-Glc. We then 
set out to investigate the cross-reactivity between the N-glucosylated adhesin antigen HMW1ct-Glc and 
anti-CSF114(N-Glc) IgG antibodies by competitive ELISA35. The possible cross-reaction between 
Inhibitors
MS Sera NBD sera
MS1 MS2 MS3 MS4 MS5 NBD1 NBD2 NBD3 NBD4
I(Glc) 8.65 ± 0.10 8.09 ± 0.56 7.98 ± 0.26 7.57 ± 0.16 7.67 ± 0.28 7.20 ± 0.29 6.92 ± 0.30 6.37 ± 0.52 6.83 ± 0.26
I < 5.0 < 5.0 < 5.0 7.87 ± 0.24 < 5.0 6.86 ± 0.37 7.84 ± 0.42 5.92 ± 0.52 7.09 ± 0.26
Table 1.  Calculated pIC50 values for inhibitors of anti-I(Glc). Values are reported as calculated pIC50 ± the 
standard error (SEM) in 5 representative MS and 4 NBD sera.
Figure 3. Immunoaffinity purification of antibodies from one representative NBD and one MS serum.  
(a) Schematic process of antibody fractionation. (b) SP-ELISA of antibody fractions obtained from two 
sequential sepharose columns bearing the immobilized non-glucosylated I and hyperglucosylated I(Glc). 
Antigen I designated as solid bars and antigen I(Glc) designated as gray bars. In the case of NBD serum, flow 
through 1 (FT1) and eluted fraction 2 (Elu2) were collected. In the case of MS serum, flow through 1 (FT1), 
eluted fraction 2 (Elu2), flow through 3 (FT3), eluted fraction 4 (Elu4) were collected. Each point is mean ± s.d. 
for n = 3 independent experiments. The ELISA absorbance in serum can be explained considering that IgG 
concentration in the whole sera (10 mg/ml) is 300 times higher than in eluted fractions (0.03 mg/ml).
Inhibitor MS1 MS2 MS3 MS4 MS5 Mean value 95% C.I.*
1 I(Glc) 9.27 ± 0.07 8.88 ± 0.15 8.42 ± 0.28 9.34 ± 0.19 9.45 ± 0.16 9.07 ± 0.42 8.547–9.597
2 II(Glc) 8.59 ± 0.04 8.93 ± 0.18 9.94 ± 0.19 9.34 ± 0.10 9.77 ± 0.20 9.31 ± 0.56 8.614–10.01
3 III(Glc) 8.71 ± 0.11 8.28 ± 0.15 9.34 ± 0.38 9.25 ± 0.12 8.89 ± 0.08 8.89 ± 0.43 8.361–9.427
4 IV(Glc) 10.14 ± 0.03 8.26 ± 0.08 not tested not tested 8.56 ± 0.27 8.99 ± 1.01 6.478–11.50
5 V(Glc) 7.59 ± 0.16 7.21 ± 0.07 6.69 ± 0.14 6.89 ± 0.05 7.56 ± 0.27 7.19 ± 0.40 6.692–7.684
6 I < 6.0 < 6.0 < 6.0 < 6.0 < 6.0 n.a. n.a.
7 II < 6.0 < 6.0 < 6.0 < 6.0 < 6.0 n.a. n.a.
8 III < 6.0 6.80 ± 0.23 < 6.0 6.17 ± 1.06 6.44 ± 0.73 6.47 ± 0.32 5.685–7.255
9 IV < 6.0 < 6.0 not tested not tested < 6.0 n.a. n.a.
10 V < 6.0 < 6.0 6.41 ± 0.44 < 6.0 < 6.0 n.a. n.a.
11 CSF114(N-Glc) 7.25 ± 0.07 7.17 ± 0.09 8.05 ± 0.26 7.69 ± 0.14 7.66 ± 0.53 7.56 ± 0.36 7.118–8.010
Table 2.  Calculated pIC50 values for inhibitors toward anti-CSF114(N-Glc) IgG antibodies. Values are 
reported as calculated pIC50 ± the standard error (SEM) of the N-glucosylated adhesin antigens (I(Glc)-V(Glc)) 
and the corresponding non-glucosylated analogs (I-V) used as inhibitors of anti-CSF114(N-Glc) antibodies in 5 
representative MS sera. *95% confidence interval (C.I.).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:39430 | DOI: 10.1038/srep39430
anti-CSF114(N-Glc) antibodies in MS patient sera and the N-glucosylated antigens (I(Glc)-V(Glc)) was tested 
in a selected population of representative MS patient and NBD sera (Table 2). Results clearly showed that the 
hyper N-glucosylated I(Glc) was able to inhibit the binding of anti-CSF114(N-Glc) IgG antibodies in sera from 
a selected population of representative MS patients (mean pIC50 = 9.07 ± 0.42). In contrast, non-glucosylated 
protein I did not inhibit, or only inhibited MS serum binding at significantly higher concentrations (mean 
pIC50 = < 6.0), confirming the fundamental role of the N-glucosyl moieties on the adhesin protein for the inter-
action with anti-N-glucosyl antibodies in MS sera (Table 2, entries 1 and 6, respectively). In order to more spe-
cifically define the N-Glc epitope(s) involved in antibody recognition, the HMW1ct mutants (II(Glc)-V(Glc) 
and II-V) were also tested for their binding to anti-CSF114(N-Glc) IgG antibodies. Interestingly, antigens 
II(Glc)-IV(Glc), containing 5/6 and 4 differentially-spaced N-Glc moieties, displayed a similar binding affinity 
to the hyper-N-glucosylated antigen I(Glc) (Table 2, entries 2–4 and 1, respectively), with negligible binding of 
the non-glucosylated counterparts II-IV (Table 2, entries 7–9). Antigen V(Glc) however, displaying only two 
N-Glc moieties, showed a significant reduction in binding affinity to anti-CSF114(N-Glc) IgG antibodies (mean 
pIC50 = 7.19 ± 0.40), to an extent comparable to the binding affinity of CSF114(N-Glc) itself (Table 2, entries 
5 and 11, respectively). As the difference in affinity between antigens I(Glc) and V(Glc) is almost 2 log units 
(Table 2, entries 1 and 5, respectively), this is a very significant decrease, even taking into account the different 
number of N-Glc epitopes in the various samples (7/8/9 versus 2, respectively). Convincingly, a similar trend in 
binding of antigens I-V and I(Glc)-V(Glc) with anti-I(Glc) antibodies was obtained in a similar inhibition exper-
iment (Supplementary Fig. 6). Moreover, Surface Plasmon Resonance (SPR) studies revealed a similar binding 
affinity of I(Glc) and CSF114(N-Glc) for purified anti-I(Glc) IgG antibodies, confirming their cross-reactivity 
(Supplementary Fig. 7). These results strongly indicate that both the number and the specific presentation of the 
N-glucosyl moieties play an important role in antibody recognition in MS patient sera.
Anti-I(Glc) antibodies bind to myelin in the CNS. To demonstrate the biological significance of the 
binding of antibodies from MS patient sera to hyperglucosylated antigen I(Glc), immunohistochemistry experi-
ments on normal and experimental autoimmune encephalomyelitis (EAE) mouse spinal cords were performed. 
In this experiment, the cross-species ability of purified anti-hyperglucosylated adhesin IgG antibodies from sera 
of a representative MS patient to recognize CNS tissue was compared to the binding of the total IgG fraction from 
NBD sera. The CNS myelin of mice is an accepted system for screening pathogenically relevant and immuno-
reactive antigens because these antigens are well conserved relative to the human counterparts. Moreover, the 
murine tissues are available for rapid processing thereby avoiding problems with protein degradation as is often 
encountered in human brain autopsy samples. Additionally, EAE is a relevant and broadly accepted model for MS 
and considerable insight into MS pathophysiology has been achieved using this model4. Anti-hyperglucosylated 
adhesin antibodies were incubated with spinal cord sections of naïve healthy mice and of mice inflicted with EAE, 
harvested three weeks after disease induction, when hind and forelegs were paralyzed (grade 4)36. In parallel, spi-
nal cord sections of the same mice were incubated with the total IgG fraction from the normal blood donor sera. 
It should be noted that purified anti-I(Glc) antibodies from the representative MS1 patient serum were used in 
immunohistochemistry experiments (Figs 4a and 5a), while the total IgG fraction from an NBD representative 
serum (NBD1) was used in the control experiment depicted in Figs 4b and 5b because the titer of anti-I(Glc) anti-
bodies, purified by immunoaffinity chromatography, is too low in NBD serum. The anti-I(Glc) antibodies posi-
tively stained the mouse spinal cord (Figs 4a and 5a), whereas no staining was observed in the control experiment 
with IgGs from NBD (Figs 4b and 5b). Interestingly, while it cannot be excluded that negative staining with IgGs 
from NBD might be simply due to insufficient titer to anti-I(Glc) antibodies, staining by anti-I(Glc) antibodies 
from MS1 was restricted to the white matter region, overlapping the myelin (depicted by staining with antibodies 
to myelin basic protein, MBP). Intense anti-I(Glc) staining was particularly manifested in the spinal cord white 
matter of naïve mice, whereas in EAE-mice, at sites of inflammation (depicted by Hoechst nuclear staining of 
the infiltrating cells), staining by anti-I(Glc) antibodies was lost, in parallel to the demyelination. Anti-I(Glc) 
antibodies did not bind to the spinal cord neurons located in the grey matter, or to the myelin in the peripheral 
nervous system. These findings indicate that anti-glucosylated adhesin antibodies from MS patients can bind to 
the myelin in the mouse CNS. The observation that after demyelination in the EAE model little myelin remains 
for recognition by anti-I(Glc) antibodies further supports the hypothesis that these antibodies recognize myelin.
Discussion
Genome sequencing, in combination with biochemical, bioanalytical, and bioinformatic approaches37–40 has 
uncovered the diverse glycoconjugate repertoire of many microbial pathogens and revealed a prevalence of 
prokaryote-specific saccharides and glycosidic linkages in the conjugated glycan structures decorating bacterial 
cell surfaces41–44. The abundance of these non-human glycoconjugates on the cell surfaces of infectious micro-
organisms makes them potential molecular candidates for promoting immune system evasion by molecular 
mimicry of host cell-surface glycans45. The same molecular mimicry that affords the pathogen avoidance from 
immune surveillance however, may present serious additional consequences to the host organism stemming 
from the same host glycans being recognized as foreign thus activating an autoimmune response. One of the best 
understood examples of a microbial infection leading to a post infection autoimmune disease comes from studies 
on the Gram-negative bacterium Campylobacter jejuni, which is the leading cause of gastroenteritis in humans46. 
While the actual C. jejuni infection symptoms clear in a few days, epidemiological studies show a significant cor-
relation between C. jejuni infections and Guillian-Barré syndrome (GBS), which manifests in acute neuromuscu-
lar paralysis and approximately 25% of GBS patients have developed symptoms after infection with C. jejuni47. For 
GBS there is now compelling evidence, including a significant and disease-correlated increase in anti-GM1 IgG 
titers, that molecular mimicry of the host GM1 ganglioside by the C. jejuni lipooligosaccharide ultimately results 
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in the autoimmune neuropathy condition48. Moreover, Sakiyama et al. recently reported 4 cases of encephalomy-
elitis correlated to an unknown pathogen. On the basis of the genomic studies and the ultrastructural analysis of 
the pathogen, they proposed a new disease entity having archaeal features49.
The current study starts from the critical observation that antibody titers against a glycopeptide designated as 
CSF114(N-Glc) are increased in the sera of MS patients14. In a longitudinal study of untreated relapsing-remitting 
multiple sclerosis (RR-MS) patients for up to 6 months, it was demonstrated that levels of anti-CSF114(N-Glc) 
antibodies paralleled intensity of clinical activity and number of brain lesions positive to Gd-enhanced Magnetic 
Resonance Imaging14. Despite many efforts to clarify the specificity or functional significance of antibodies in MS, 
their origin and role remain elusive. Therefore, the possibility of characterizing antibodies cross-reacting with 
bacterial antigens, might contribute to the understanding of immunopathology50.
With these considerations in mind, we turned our attention to the bacterial glycoconjugates of human path-
ogens. N-Glc is a prokaryote-specific modification that is found in selected Gram-negative bacteria, where it is 
most commonly found on cell-surface proteins such as (autotransporter) adhesins – biosynthesized as part of 
the three-protein HMW cluster including the N-glucosyl tranfserase HMW1C. These adhesins are abundantly 
displayed on the bacterial cell surface, and because they are often extensively glycosylated, the glycan structures 
Figure 4. Immunofluorescent staining of mouse spinal cord sections by anti-I(Glc) antibodies. Coronal 
lumbar spinal cord sections from naïve mice as well as from mice inflicted with experimental autoimmune 
encephalomyelitis (EAE, grade 4, three weeks after disease induction), were incubated with: (a) anti-I(Glc) 
antibodies from a representative MS patient serum, (b) Total IgG fraction from a normal donor (NBD). 
Binding to the spinal cord tissue was indicated by fluorescent labeling with anti-human antibody (red). Note 
that the positive staining of anti-I(Glc) antibodies overlaps the myelin depicted by staining with antibody to 
myelin basic protein (MBP, green). Staining by anti-I(Glc) antibodies is lost in the spinal-cord white matter 
(WM) of EAE-mice, at sites of inflammation (depicted by Hoechst nuclear staining of the infiltrating cells, 
blue), in parallel to the demyelination. Anti-I(Glc) antibody binding is restricted to the spinal cord WM 
while no staining is observed in the gray matter (GM) or in the periphery ventral roots (VR). Arrows depict 
inflammatory sites in sections of EAE mice. The linear structures stained at the center of gray matter (a) are 
non-relevant staining resulting from folds in the tissue.
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are likely to be presented in a multivalent manner, which would potentially favor the emergence of a robust 
immunologic response.
We present evidence of a strong connection between MS and the pathogen Haemophilus influenzae, which is a 
common cause of upper respiratory infection in humans. The biochemical construction of N-glucosylated protein 
antigens using the biosynthetic machinery from H. influenzae and A. pleuropneumoniae was critical to isolate 
purified antibodies from MS patient sera. Evidently, introduction of at least four N-glucosyl moieties on the 
H. influenzae C-terminal adhesin fragment HMW1ct(1205–1526) is essential for the identification of the highest 
affinity antibodies in multiple sclerosis. The purified MS antibodies were used in SP-ELISA titrations, inhibition, 
and SPR experiments, to demonstrate specific recognition of the N-Glc epitope. Finally, in immunohistochemis-
try experiments, the purified MS antibodies showed intense and specific staining to the myelin in the spinal cord 
white matter, in contrast to the absence of staining by total IgG antibodies from normal blood donor.
We conclude that the H. influenzae hyperglucosylated adhesin I(Glc) is the first example of an N-glucosylated 
antigen that can be considered a relevant candidate for triggering pathogenic antibodies in multiple sclerosis. Our 
data are in agreement with a recent report on microbial infections and degenerative neurodiseases51 supporting 
that microbes can cause chronic as well as acute diseases. Some microbes can remain latent in the body with the 
Figure 5. A higher magnification of the white matter taken from the different sections in Fig. 4, showing 
in further detail the immunofluorescent staining by anti-I(Glc) antibodies. Coronal lumbar spinal cord 
sections from naïve mice as well as from mice inflicted with experimental autoimmune encephalomyelitis 
(EAE, grade 4, three weeks after disease induction), were incubated with: (a) anti-I(Glc) antibodies from a 
representative MS patient serum, (b) Total IgG fraction from a normal donor (NBD). Binding to the spinal cord 
tissue was indicated by fluorescent labeling with anti-human antibody (red). Note that the positive staining 
of anti-I(Glc) antibodies overlaps with the myelin depicted by staining with antibody to myelin basic protein 
(MBP, green). Staining by anti-I(Glc) antibodies is lost in spinal cords of EAE-mice, at sites of inflammation 
(depicted by Hoechst nuclear staining of the infiltrating cells, blue), in parallel to the demyelination.
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potential for reactivation, the effects of which might occur years after initial infection. People can be infected but 
not necessarily affected, such that ‘controls’, even if infected, are asymptomatic.
With these new findings, the foundation is established for determining the nature of the molecular mim-
icry mechanism, and for elucidating the human protein target(s), which are cryptic mimics recognized by 
anti-hyperglycosylated adhesin antibodies in Multiple Sclerosis.
Methods
Patient criteria and descriptions. Multiple Sclerosis (MS) patient sera samples were collected in 
two Multiple Sclerosis Centers: The Multiple Sclerosis Clinical Care and Research Centre, Department of 
Neurosciences, Reproductive Sciences and Odontostomatology, Federico II University (Naples, Italy) and the 
Azienda Ospedaliera Universitaria Careggi, Clinica Neurologica, University of Florence (Florence, Italy). Normal 
Blood Donor (NBD) patient sera samples were collected by F. Lolli at the Azienda Ospedaliera Universitaria 
Careggi, Immunotransfusion Centre, University of Florence (Florence, Italy).
MS patient sera samples were collected from 126 patients (42 males) aged from 19 to 65 years (mean age 
39 years). The patients fulfilled established international diagnostic criteria52. Total IgM and IgG titers were 
measured by SP-ELISA in all the MS patient sera samples. Five relapsing-remitting MS patients (MS1-MS5, age 
35 to 58 years; 3 males) were subsequently selected for detailed analysis among patients displaying IgG > 1 to 
CSF114(N-Glc) and IgG > 1.5 to I(Glc). MS1, displaying high IgG titer also to I (> 1), was selected for immuno-
affinity purification of anti-I(Glc) antibodies used for immunohistochemistry and Surface Plasmon Resonance 
experiments. The age of disease onset ranged from 10 to 40 years. The clinical findings, the EDSS and the clinical 
course of the MS patients were evaluated at the time of blood sampling and follow-up. MRI examinations were 
made for diagnostic purposes with typical MS findings. In seropositive patients, disease duration was between 
6 and 9 years, the EDSS score was between 2.5 and 4. Four of these patients (MS2-MS5) were in treatment with 
interferon-beta and MS1 was an untreated patient.
As controls, we collected 112 Normal Blood Donor (NBD) sera samples matched for age and sex with MS 
patient sera samples. Total IgM and IgG titers were measured by SP-ELISA using all the NBD sera samples as 
controls. Four NBD sera samples (NBD1-NBD4) were subsequently selected for detailed analysis among those 
displaying IgG > 1 to I(Glc) and I; two out of these four were IgG negative to CSF114(N-Glc) (NBD1 and NBD3), 
while two were positive (NBD2 and NBD4). NBD1 was selected as control in immunoaffinity purification 
experiments.
The present study was conducted in accordance with the Declaration of Helsinki. All experimental protocols 
performed were approved by the Ethics Committee of the University Hospitals above mentioned involved in this 
study. Written informed consent forms were obtained from all MS patients and NBD subjects for sampling and 
research. All the methods were carried out in accordance with relevant approved guidelines and regulations.
Cloning. The gene encoding the HMW1ct corresponding to amino acids 1205–1536 was synthesized com-
mercially after gene optimization for E. coli, and obtained in the pUC57 vector (Genscript). Using KpnI and SacI 
restriction sites, the gene was amplified by PCR and ligated into the pET-45b (+ ) vector encoding carbenicillin 
resistance (Novagen). A tryptophan residue was introduced in the N-terminal overhang by transforming Gly to 
Trp using QuickChange mutagenesis. HMW1ct mutants were designed by either substituting the Asn residue for 
Glu (N → Q) or substituting the Ser/Thr residue for Ala (S/T → A). The resulting mutants were constructed using 
the Quik Change II site-directed mutagenesis kit and the mutagenic primers sets (Supplementary Table 3) accord-
ing to the manufacturer’s instructions. The gene encoding the HMW1C-like glucosyltransferase was obtained 
from Actinobacillus pleuropneumoniae genomic DNA (ATCC: 27088D-5) and inserted into the pET-24a (+ ) 
vector (Novagen), as described previously33,26. The vector-encoded C-terminal His6-tag was removed by intro-
ducing a stop codon after the hm1C gene using the primers in Supplementary Table 4 in a PCR protocol, and 
reintroducing the amplified gene in the pET-24a (+ ) to retain kanamycin resistance. The plasmids used in this 
study are described in Supplementary Table 5.
General protocol for the preparation of N-glucosylated HMW1ct proteins via co-expression of 
HMW1ct and HMW1C. Transformation of the two plasmids pET45::His6-hmw1ct and pET24::hmw1C-stop 
was initiated by mixing both plasmids (0.5 μ L) into BL21 cells (50 μ L). After heat shock, the cells were diluted 
with SOC media (200 μ L) and incubated at 37 °C for 90 min. A 100 μ L aliquot was plated out on carbenicillin/
kanamycin/chloramphenicol plates and incubated at 37 °C overnight. Colonies were selected for growing in a 
5-mL overnight culture. Subsequently, the bacteria were grown to an OD600 of 0.6–0.8 at 37 °C, and expression 
was induced with 1 mM IPTG, followed by incubation at 16 °C overnight. Subsequently, bacterial cells were har-
vested, resuspended in lysis buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 10% glycerol) and disrupted using 
sonication (3 × 1 min at 40% amplitude) in the presence of protease inhibitor (10 μ L per gram of cells). After cen-
trifugation at 35,000 × g for 65 min at 4 °C, the clear supernatant was applied to a suspension of Ni2+-NTA beads 
at 4 °C for 1 h. The beads were transferred to a frit-containing column, the flow-through was collected, and the 
beads were subsequently washed with washing buffer (30 mM imidazole, 50 mM HEPES pH 7.5, 300 mM NaCl, 
5% glycerol) and both glucosylated HMW1ct and HMW1C were eluted with elution buffer (300 mM imidazole, 
50 mM HEPES pH 7.5, 300 mM NaCl, 5% glycerol). Protein fractions were pooled and dialyzed into 20 mM Tris 
pH 8.0 and 20 mM NaCl. The protein mixtures were loaded onto a 5-mL anion exchange column (HiTrap Q FF) 
and eluted with a linear gradient of 20 mM Nacl-1M NaCl using an AKTA FPLC system, to facilitate separation 
of glucosylated HMW1ct and HMW1C. The fractions containing I(Glc) were pooled, concentrated, and dialyzed 
(50 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol) to give a total yield of ~16 mg of I(Glc) from a 1 L culture.
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In vitro glucosylation of V(Glc). Using the co-expression protocol, over-glucosylation of antigen V was 
observed. Instead of glycosylation of the two remaining sites, a mixture of proteins with 2, 3, and 4 glucose units 
was observed in a ratio of 2:2:1 respectively. Glucosylation of non-canonical sites has been reported previously26 
and it was expected to be a result of the high expression levels of HMW1C. Using an in vitro glucosylation proto-
col, the glucosylation level of antigen V was greatly reduced, resulting in pure twice glycosylated antigen V(Glc).
After optimization studies, in which the concentration of V and equivalents of HMW1C were varied, optimal 
conditions were obtained to produce V(Glc) with only two Glc moieties: 50 μ M V, 500 nM HMW1C, 500 μ M 
UDP-Glc in a final volume of 10 mL. The reaction was incubated at RT overnight, and subsequently purified using 
Ni2+-NTA.
Tryptic digest and MS/MS analysis of I(Glc). A sample containing 4.6 μ g of the purified I(Glc) was 
diluted with 100 μ L 8 M urea (in 50 mM ammonium bicarbonate pH 8.5). The sample was heated at 55 °C for 
1.5 h, after which time 12 μ L 300 mM iodoacetamide in ammonium bicarbonate was added. The mixture was 
incubated at RT in the dark for 60 min, and subsequently transferred to a 10,000 MWCO spin filter. A 300 μ L 
aliquot of ammonium carbonate was added, and the mixture was centrifuged at 14,000 × g to reduce the volume 
in the filter to below 50 μ L. This was repeated with 300 μ L and 400 μ L ammonium carbonate, followed by transfer 
of the residue to a clean eppendorf tube. Then 6 μ L of a freshly prepared trypsin solution (1 μ g per 30 μ L 50 mM 
ammonium carbonate) was added to the sample, and the mixture was incubated at RT overnight. Subsequently, 
5.6 μ L 10% formic acid in water was added to acidify the mixture, and it was analyzed using LC-MS/MS 
(Supplementary Table 2).
Measurement of antibody affinity by competitive ELISA and statistical analysis. The exper-
imental strategy involves immobilization of hyperglucosylated antigen I(Glc), followed by incubation with a 
serum in the presence of a concentration range of the competing species (in this case, antigens I(Glc) or I). The 
resultant antibody binding to the immobilized antigen is quantified using a fluorescent secondary antibody, and 
the absorbance units across the concentration range can be converted to a pIC50 value (Table 1). The relative 
mean affinity of antibodies was measured by following the method published by Rath et al.35. The semi-saturating 
dilution was calculated from the preliminary titration curves (absorbance, 0.7). At this dilution, antibodies 
were pre-incubated with increasing antigen concentrations (1 h at 25 °C). Bound antibodies were revealed by 
SP-ELISA, and the relative mean affinity of those antibodies for the different inhibitors was expressed by pIC50 
values calculated through non-linear regression curve fit using GraphPad Prism 6.0.
Sequential immunoaffinity chromatography. I(Glc) (3 mg) and the non-glucosylated adhesin I (3 mg) 
were dissolved in NaHCO3 (0.1 M, 3 mL) containing 0.5 M NaCl, pH 8.3, and were coupled to CNBr-Sepharose 
(200 mg) matrix (Sigma). The NBD1 and the MS1 sera (3 mL) positive to both CSF114(N-Glc) and I(Glc) (diluted 
1:10 in PBS) were passed three times through the non-glucosylated adhesin I column pre-equilibrated with PBS, 
pH 7.2. In the case of MS1, the un-retained flow-through fraction was directly loaded onto the column and recir-
culated three times. Adsorbed antibodies were eluted using glycine (0.1 M, 10 mL, pH 2.6) and recovered in D-PBS 
buffer pH 7.2. Protein content of specific anti-I(Glc) purified IgG antibodies was determined to be 46.5 μ g/ml 
by UV spectroscopy measuring the absorbance of the solution at 280 nm (Shimadzu UV-1601PC) considering 
that the extinction coefficient is 1.4 for a solution of 1 mg/mL. The efficiency of this sequential immunoadsorbtion 
was confirmed by SP-ELISA.
The total IgG fraction from NBD1 serum was obtained by Protein G affinity chromatography using a pre-
packed column (Amersham Biosciences, NJ) according to manufacturer’s instructions. Protein content of the 
total IgG fraction from NBD1 serum was determined to be 1.7 mg/mL using the method above described.
SP-ELISA for antibody titer determination. Specific anti-I(Glc) IgG and anti-I antibodies were evalu-
ated in SP-ELISA following a previously validated protocol14. Although the use of SP-ELISA may result in dimin-
ished specificity and statistical significance of antibody recognition due to the possibility of multiple non-relevant 
epitopes in the protein, it allows screening of a large number of patient sera in a relatively short time using mini-
mal amounts of surface-coated antigen.
Biosensor Analysis. All experiments were carried out on a Biacore T100 (GE Healthcare, Sweden). All 
solutions and buffers were prepared with milliQ water obtained by a Sartorius system (arium 611 VF). Sensor 
chips CM5 (carboxymethylated dextran), amine coupling kit (EDC/NHS (50:50), and Running Buffer HBS-EP+ 
10× (0.1 mol/L HEPES, 1.5 mol/L NaCl, 30 mmol/L EDTA, 0.5% v/v p20) were purchased by GE Healthcare. 
Running Buffer was diluted ten times with milliQ water at pH 7.4. Sodium acetate and sodium hydroxide (Carlo 
Erba, Milano). Each antigen was immobilized on a different channel of the chip CM5-type according to the 
amine coupling strategy using a concentration of 10 μ g/mL in immobilization buffer at 10 μ L/min for 420 s and 
60 s. Unreacted groups on the sensor chip surface were blocked by injecting 60 s-pulses of ethanolamine-HCl 
(1 M pH 8.5) until complete deactivation. The reference channel was activated and subsequently blocked with 
ethanolamine. The selected buffers and the immobilized protein levels are reported in Supplementary Table 6. For 
kinetic and affinity studies with purified antibodies, a CM5 chip was used, and the data was collected at 25 °C at 
a flow rate of 30 mL/min. The anti-I(Glc) IgG antibody fraction (at initial concentration tested by absorbance at 
280 nm) was diluted in running buffer to final concentrations of 16.6, 33.3, 66.6, and 133.3 nM. Diluted samples 
were injected over each immobilized antigen according to the method published elsewhere. Kinetic and affinity 
parameters were obtained using Biacore Evaluation Software 2.0 according to the 1:1 binding model.
Immunohistochemistry. Lumbar segments of spinal cords from naïve mice, as well as from mice inflicted 
with EAE induced by the 35–55 peptide of myelin oligodendrocyte glycoprotein (MOG) as described36, were 
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paraffin embedded and sectioned at coronal position (4 μ ). Deparaffinized and antigen retrieved (citric acid 
pH 6) sections were pre-incubated in blocking solution containing 20% serum and 0.2% Triton (1 h, RT), and 
then incubated (72 h, 4 °C) with anti-I(Glc) IgG antibodies from the representative MS patient serum or with 
total IgG fraction from the normal blood donor, as well as with rat anti-myelin basic protein antibodies (MBP, 
Abcam, Cambridge United Kingdom). The second step was performed by labelling with species-specific anti-
bodies (Jackson ImmunoResearch, West Grove, PA, USA), namely, biotinylated anti-human antibody followed 
by Cy3-conjugated streptavidin, and with a Cy2-conjugated anti-rat antibody. We used 535/40 nm band pass 
filter for detection of Cy2 and 605/50 nm band pass filter for detection of Cy3. Control slides were incubated with 
the non-relevant fluorescent secondary anti-IgG antibody. Sections were counter-stained with Hoechst 33258 
(Molecular Probes, Eugene, OR, USA) for nuclear staining. Stained sections were examined and photographed 
by fluorescence microscope (E600, Nikon, Tokyo, Japan), equipped with Plan Fluor objectives connected to CCD 
camera (DMX1200 F, Nikon). Images were assembled using Adobe Photoshop (Adobe Systems).
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